SCHEMBL23686012

SCHEMBL23686012

O=S(=O)(S)c1ccc(C2CCCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.59
HTT P42858 4/20 0.59
SMN1; SMN2 Q16637 6/20 0.53
ALDH1A1 P00352 4/20 0.51
MAPT P10636 3/20 0.51
APOBEC3A P31941 1/20 0.51
APOBEC3G Q9HC16 1/20 0.51
TP53 P04637 1/20 0.51
ATM Q13315 1/20 0.51
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TSHR P16473 2/20 0.47
XBP1 P17861 1/20 0.47
PTGES2 Q9H7Z7 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HAO1 Q9UJM8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10182181 0.83 LMNA (0.68) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL10180298 0.81 LMNA (0.65) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL6268570 0.80 LMNA (0.64) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1931626 0.80 LMNA (0.59) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL12256487 0.80 LMNA (0.59) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL23686014 0.80 LMNA (0.59) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL14341830 0.80 LMNA (0.59) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL10182153 0.80 LMNA (0.59) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL21423060 0.80 LMNA (0.64) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL11677845 0.80 LMNA (0.59) LMNAHTTSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210227827-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION NEW YORK BLOOD CENTER, INC. 2021-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210227827-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION MGMT, O60361, SAMHD1 LMNA 1374/4885HTT 1589/4885SMN1; SMN2 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.